RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments ( effects of the treatment.Consequently...)

RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments

effects of the treatment. Consequently, an agent that reduces these toxicities and also has a significant direct anti-cancer effect would likely gain rapid acceptance in a variety of first-line and second-line treatment settings.

RTA 402 has recently begun Phase 2 clinical studies in cancer patients. An ongoing Phase 1 study in cancer patients has indicated that RTA 402 has potent single-agent anti-cancer activity in patients with several different types of tumors, is well tolerated with only mild, transient side effects, and suppresses its target proteins NF-kB and STAT3 in human tumors. A Phase 1/2 study of RTA 402 in combination with gemcitabine is underway in patients with pancreatic cancer. Analogues of RTA 402 are in advanced preclinical development for cancer, anti-inflammatory, and neurodegenerative indications.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on selecting and discovering promising early drug development opportunities and translating them into successful marketed drugs that target major unmet clinical needs in cancer, inflammation and neurodegenerative disease. The company's two lead programs are entering advanced clinical trials for deadly, late-stage cancers. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform using protein misfolding, identified as a key factor in cancer and neurodegenerative disease, to feed its pipeline of small molecule therapeutic candidates. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com

Contact

Media:
For Reata Pharmaceuticals, Inc.
Kathryn Morris, 845-635-9828
'"/>

Page: 1 2 3
Related medicine technology :

1. Gabapentin Shown Effective for Fibromyalgia Pain
2. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
3. CEL-SCIS CEL-1000 Shown to Significantly Enhance Immune Response Against Avian Flu Antigen in Animals
4. Efficacy and Safety Profile of Basileas Alitretinoin for Severe Refractory Chronic Hand Eczema Confirmed by Data Shown at European Dermatology Congress
5. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
6. RTA 402 Shown to Inhibit STAT3 in Animal Model and Holds Significant Promise for Treating Breast Cancer
7. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
8. Cethromycin Shown Effective Against Anthrax in Study
9. CEL-SCIs Cel-1000 Shown to Significantly Enhance Immune Response Against Hepatitis B Antigen in Animals
10. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
11. Novavax Pandemic Flu Vaccine Provided Protection Against a Lethal Challenge of Live Virus, Pre-Clinical Data Show

Post Your Comments:

(Date:11/23/2009)...ingtheFDAapprovalsoftwonewtherapiesforNon-Hodgkin,...atedtoincludeofatumumab(Azerra(TM),GlaxoSmithKline...leukemia(CLL)andromidepsin(Istodax(R),GloucesterPh...cutaneousT-celllymphoma(CTCL). ,, FORTWASHINGTO...pprovalshavepromptedtheNationalComprehensiveCancer...

(Date:11/23/2009)...K,Nov.23/PRNewswire/--Reportlinker.comannouncestha.... ,, AnesthesiaDisposables-AWorldMarketReview ...thesia-Disposables---A-World-Market-Review.html#ut...aign=prnewswire ,, Globalgeneralanesthesiad...ration.Despitetheconsiderablerisewitnessedingenera...

(Date:11/23/2009)...DLANDS,Texas,Nov.23/PRNewswire-FirstCall/-- Lexico...aythattop-linedatafromitsPhase2clinicalstudywith L...syndrome(IBS)willbepresentedatGASTRO2009inLondonth...improvementinIBSsymptoms,willbepresentedbyDr. Phil...evelopment,onNovember25,2009at2:30pmlocaltimeatthe...

Breaking Medicine Technology:NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 2 NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options 3 Reportlinker Adds Anesthesia Disposables - A World Market Review 2 Reportlinker Adds Anesthesia Disposables - A World Market Review 3 Reportlinker Adds Anesthesia Disposables - A World Market Review 4 Reportlinker Adds Anesthesia Disposables - A World Market Review 5 Reportlinker Adds Anesthesia Disposables - A World Market Review 6 Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 2 Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009 3 Galil Medical Announces Establishment of Global Headquarters in Minneapolis MN 5093 1 Galil Medical Announces Establishment of Global Headquarters in Minneapolis MN 5093 2 Michael J Fox Foundation Funded Team Pursuing Glutamate Based Treatment for Parkinsons Disease Hits Major Milestone 5090 1 Michael J Fox Foundation Funded Team Pursuing Glutamate Based Treatment for Parkinsons Disease Hits Major Milestone 5090 2 GenVec Receives National Cancer Institute Grant to Expand Cancer Program 5087 1 GenVec Receives National Cancer Institute Grant to Expand Cancer Program 5087 2

[0] NCCN Updates NHL Guidelines to Incorporate FDA Approvals of New Treatment Options [0] Reportlinker Adds Anesthesia Disposables - A World Market Review [0] Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009

... international hub for collaborative research, bio...e Wayne State University research and technology...mmercialization lab in Michigan. The Wayne County ...ld of Wayne County Executive Robert Ficano, who pu...500-square-foot stem cell research facility in his...

...or less , , PRINCETON, N.J., Feb. 13 Derma Scie...er of advanced wound care products, announced toda... case series on eleven non-healing venous leg ulce...ile being managed with such therapeutic modalities...l dressings, antibiotic therapy, and hyperbaric ox...

Other Medicine Technology:Wayne County Partners With TechTown to Launch Global Stem Cell 'Innovation and Commercialization Lab' 2 MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 2 MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series 3

Wayne County Partners With TechTown to Launch Global Stem Cell 'Innovation and Commercialization Lab'MEDIHONEY(TM) Dressings Shown to Help Improve Outcomes of Non-Healing Venous Leg Ulcers in Recent Case Series

(Date:11/23/2009)... After suffering from women,s hair loss for almost... and she,s sharing her progress and the secret beh...ugh the release of her video diaries which include... her treatment. , (PRWeb ...ferer Zsanett Siklosi has released the video diari...

(Date:11/23/2009)...TargetIndividualsintheRecommendedPriorityGroups ,...--TheDepartmentofHealthannouncedtodaytheywillcondu...eHealthCentersinDelaware,Lancaster,andLehighcounti...inewillbeadministeredforfreetoindividualsinthereco...hevaccine.Thedepartmentasksthatonlyindividualsinth...

(Date:11/23/2009)...care professionals enjoy a pay raise for a job wel...s for health care performance may actually backfir... performance ratings for 25 medical groups across ...unch of a statewide pay-for-performance program in... productivity. , Reporting in the December ed...

(Date:11/23/2009)...t woman to head the agency, said lives could be at...s) -- The fallout from last week,s controversial r...e mammogram testing for breast cancer continues, w...of Health advising women to ignore the guidelines....ause unequivocally this will increase the number o...

(Date:11/23/2009)...caretofinance"reform"isamoraloutrage ,, WASHI...eDemocratsmovedforwardtobeginthedebateontheirhealt...pporterstronggrassrootssenioradvocacygroup,iscalli...testthemassivecutstoMedicare.RetireSafePresidentTh...issuesliketaxes,abortion,andimmigration,whilethesi...

Breaking Medicine News(10 mins):Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 2 Health News:Women's Hair Loss Treatment Results Captured on Video to Inspire Others 3 Health News:Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties 2 Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 2 Health News:Medical 'pay for performance' programs help improve care -- but not always, study finds 3 Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 2 Health News:Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says 3 Health News:RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care 2

[0] Women's Hair Loss Treatment Results Captured on Video to Inspire Others [0] Pennsylvania Department of Health Announces Additional H1N1 Vaccination Clinics in Delaware, Lancaster, Lehigh Counties [0] Medical 'pay for performance' programs help improve care -- but not always, study finds [0] Women Should Ignore New Mammogram Guideline, Ex-NIH Chief Says [1] RetireSafe Calls on Seniors to Grab their Bullhorns to Save Medicare from Rationed Care

...enwood Systems, LLC ( http://www.GlenwoodSystems.c...h seamlessly integrates EMR and Practice Manage...ess. The product has been designed to reduce the ... Waterbury, CT (Vocus) February 26...

... affordable High Voltage Piezo Amplifier (QPA200) ...l applications, and to facilitate transducer evalu... Medford, MA (PRWEB) February 26, 2009 -- P...coustically cancel noise, or to replace solenoid v...

...n the retina that is responsible for maintaining t...as been imaged in a living retina for the first ti...yer could help doctors identify the onset of many ... ., "Our goal is to figure out why macular degene...

...harmaNet Development Group, Inc. (the "Company") (...evelopment services, today reported preliminary ne... 2008, of $1.6 million, or $0.08 per diluted share...provided in this press release is subject to recor...

...or February 26, 2009 at 10:00 a.m. EST , , , EA...ls, Inc. (Nasdaq: SVNT ) today reported financia...mber 31, 2008. For the fourth quarter of 2008, th...ad a net loss of $84.2 million, or $1.57 per share...

...ookings and continued positive cash flow from oper... AMCS ), a leader in radiology and medical image...ted unaudited financial results for the fourth qua...evenue : Total revenue for the fourth quarter of 2...

Glenwood Systems, LLC Improves Medical Billing Process with GlaceComplete Amped Up Piezos Are On The Move - Driving Piezos with an Affordable High Voltage Piezo Amplifier QPA200 'Dark cells' of living retina imaged for the first time PharmaNet Development Group Reports Fourth Quarter and Full Year 2008 Preliminary Financial Results Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results AMICAS Reports Financial Results for the Fourth Fiscal Quarter and Year Ended December 31, 2008

Gentamicin, 50 mg/ml

GENTAMICIN SULFATE, 1000X

...e is effective against gram positive and gram nega...ng with bacterial protein synthesis by binding to ...g concentration of 50 mg/L is generally non-toxic ...entler alternative to penicillin and steptomycin. ...

Gibco Gentamicin Reagent Solution (10 mg/ml) liquid

Medicine Products:

Gentamicin, 50 mg/ml GENTAMICIN SULFATE, 1000X Gentamycin Sulfate: Powder Gibco Gentamicin Reagent Solution (10 mg/ml) liquid

( effects of the treatment.Consequently...)RTA 402 Shown to Protect Animals Against Toxicities of Standard,Cancer Treatments,Health